192 related articles for article (PubMed ID: 24792437)
1. Anti-neoplastic activity of low-dose endothelial-monocyte activating polypeptide-II results from defective autophagy and G2/M arrest mediated by PI3K/Akt/FoxO1 axis in human glioblastoma stem cells.
Liu J; Liu L; Xue Y; Meng F; Li S; Wang P; Liu Y
Biochem Pharmacol; 2014 Jun; 89(4):477-89. PubMed ID: 24792437
[TBL] [Abstract][Full Text] [Related]
2. Antitumor effect of endothelial monocyte-activating polypeptide-II on human prostate adenocarcinoma in mouse xenograft model.
Reznikov AG; Chaykovskaya LV; Polyakova LI; Kornelyuk AI
Exp Oncol; 2007 Dec; 29(4):267-71. PubMed ID: 18199981
[TBL] [Abstract][Full Text] [Related]
3. Endothelial monocyte activating polypeptide II induces endothelial cell apoptosis and may inhibit tumor angiogenesis.
Berger AC; Alexander HR; Tang G; Wu PS; Hewitt SM; Turner E; Kruger E; Figg WD; Grove A; Kohn E; Stern D; Libutti SK
Microvasc Res; 2000 Jul; 60(1):70-80. PubMed ID: 10873516
[TBL] [Abstract][Full Text] [Related]
4. Synergistic damage of tumor vessels with ultra low-dose endothelial-monocyte activating polypeptide-II and neovasculature-targeted tumor necrosis factor-alpha.
Crippa L; Gasparri A; Sacchi A; Ferrero E; Curnis F; Corti A
Cancer Res; 2008 Feb; 68(4):1154-61. PubMed ID: 18281491
[TBL] [Abstract][Full Text] [Related]
5. Enhancing cytotoxic agent activity in experimental pancreatic cancer through EMAP II combination therapy.
Awasthi N; Schwarz MA; Schwarz RE
Cancer Chemother Pharmacol; 2011 Sep; 68(3):571-82. PubMed ID: 21110024
[TBL] [Abstract][Full Text] [Related]
6. Endothelial monocyte activating polypeptide II (EMAP II) enhances the effect of TNF on tumor-associated vasculature.
Kayton ML; Libutti SK
Curr Opin Investig Drugs; 2001 Jan; 2(1):136-8. PubMed ID: 11527006
[TBL] [Abstract][Full Text] [Related]
7. Antitumor effects of EMAP II against pancreatic cancer through inhibition of fibronectin-dependent proliferation.
Schwarz RE; Awasthi N; Konduri S; Caldwell L; Cafasso D; Schwarz MA
Cancer Biol Ther; 2010 Apr; 9(8):632-9. PubMed ID: 20212356
[TBL] [Abstract][Full Text] [Related]
8. Endothelial monocyte activating polypeptide II interferes with VEGF-induced proangiogenic signaling.
Awasthi N; Schwarz MA; Verma V; Cappiello C; Schwarz RE
Lab Invest; 2009 Jan; 89(1):38-46. PubMed ID: 19002109
[TBL] [Abstract][Full Text] [Related]
9. Quercetin induces growth arrest through activation of FOXO1 transcription factor in EGFR-overexpressing oral cancer cells.
Huang CY; Chan CY; Chou IT; Lien CH; Hung HC; Lee MF
J Nutr Biochem; 2013 Sep; 24(9):1596-603. PubMed ID: 23618529
[TBL] [Abstract][Full Text] [Related]
10. Celecoxib and radioresistant glioblastoma-derived CD133+ cells: improvement in radiotherapeutic effects. Laboratory investigation.
Ma HI; Chiou SH; Hueng DY; Tai LK; Huang PI; Kao CL; Chen YW; Sytwu HK
J Neurosurg; 2011 Mar; 114(3):651-62. PubMed ID: 21054139
[TBL] [Abstract][Full Text] [Related]
11. Colorectal cancer cells induce lymphocyte apoptosis by an endothelial monocyte-activating polypeptide-II-dependent mechanism.
Murray JC; Symonds P; Ward W; Huggins M; Tiga A; Rice K; Heng YM; Todd I; Robins RA
J Immunol; 2004 Jan; 172(1):274-81. PubMed ID: 14688335
[TBL] [Abstract][Full Text] [Related]
12. Involvement of endothelial monocyte activating polypeptide II in tumor necrosis factor-alpha-based anti-cancer therapy.
Lans TE; Van Horssen R; Eggermont AM; Ten Hagen TL
Anticancer Res; 2004; 24(4):2243-8. PubMed ID: 15330168
[TBL] [Abstract][Full Text] [Related]
13. Cell-surface associated p43/endothelial-monocyte-activating-polypeptide-II in hepatocellular carcinoma cells induces apoptosis in T-lymphocytes.
Faisal W; Symonds P; Panjwani S; Heng Y; Murray JC
Asian J Surg; 2007 Jan; 30(1):13-22. PubMed ID: 17337366
[TBL] [Abstract][Full Text] [Related]
14. Tumour necrosis factor receptor I (p55) is upregulated on endothelial cells by exposure to the tumour-derived cytokine endothelial monocyte- activating polypeptide II (EMAP-II).
Berger AC; Alexander HR; Wu PC; Tang G; Gnant MF; Mixon A; Turner ES; Libutti SK
Cytokine; 2000 Jul; 12(7):992-1000. PubMed ID: 10880244
[TBL] [Abstract][Full Text] [Related]
15. Additive effect of low-frequency ultrasound and endothelial monocyte-activating polypeptide II on blood-tumor barrier in rats with brain glioma.
Zhang Z; Xue Y; Liu Y; Shang X
Neurosci Lett; 2010 Aug; 481(1):21-5. PubMed ID: 20600613
[TBL] [Abstract][Full Text] [Related]
16. Cooperative antitumor effect of endothelial-monocyte activating polypeptide II and flutamide on human prostate cancer xenografts.
Reznikov AG; Chaykovskaya LV; Polyakova LI; Kornelyuk AI; Grygorenko VN
Exp Oncol; 2011 Dec; 33(4):231-4. PubMed ID: 22217713
[TBL] [Abstract][Full Text] [Related]
17. Alkylphospholipids deregulate cholesterol metabolism and induce cell-cycle arrest and autophagy in U-87 MG glioblastoma cells.
Ríos-Marco P; Martín-Fernández M; Soria-Bretones I; Ríos A; Carrasco MP; Marco C
Biochim Biophys Acta; 2013 Aug; 1831(8):1322-34. PubMed ID: 23707264
[TBL] [Abstract][Full Text] [Related]
18. Signal mechanisms underlying low-dose endothelial monocyte-activating polypeptide-II-induced opening of the blood-tumor barrier.
Li Z; Liu YH; Xue YX; Liu LB; Wang P
J Mol Neurosci; 2012 Sep; 48(1):291-301. PubMed ID: 22531886
[TBL] [Abstract][Full Text] [Related]
19. Heparan sulfate regulates the antiangiogenic activity of endothelial monocyte-activating polypeptide-II at acidic pH.
Chang SY; Ko HJ; Heo TH; Kang CY
Mol Pharmacol; 2005 May; 67(5):1534-43. PubMed ID: 15710745
[TBL] [Abstract][Full Text] [Related]
20. Endothelial monocyte-activating polypeptide-II (EMAP-II): a novel inducer of lymphocyte apoptosis.
Murray JC; Heng YM; Symonds P; Rice K; Ward W; Huggins M; Todd I; Robins RA
J Leukoc Biol; 2004 May; 75(5):772-6. PubMed ID: 14982944
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
